Amyloidosis: open trials in Sweden

13 open trials have a site in Sweden. Registry data; only the trial team decides who can take part.

NCT06128629
MAGNITUDE: A Phase 3 Study of NTLA-2001 in Participants With Transthyretin Amyloidosis With Cardiomyopathy (ATTR-CM)
Trial Treatment · Phase 3 · Intellia Therapeutics
Karolinska University Hospital, Solna · Norrlands University Hospital, Umeå
Registry updated 2026-11-04
NCT06679946
A Study to Evaluate Vutrisiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy
Trial Treatment · Phase 3 · Alnylam Pharmaceuticals
Gothenburg · Solna · Umeå
Registry updated 2026-10-21
NCT07207811
CLEOPATTRA: A Research Study to Look at the Effects of Treatment With a Medicine Called Coramitug (NNC6019-0001) in People With Heart Failure Due to Transthyretin Amyloid (ATTR) Amyloidosis
Trial Treatment · Phase 3 · Novo Nordisk A/S
Karolinska Universitetssjukhuset (Karolinska University Hospital), Huddinge · Umeå University Hospital, Umeå
Registry updated 2026-10-21
NCT07052903
TRITON-CM: A Study to Evaluate Nucresiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy
Trial Treatment · Phase 3 · Alnylam Pharmaceuticals
Sahlgrenska University Hospital-Vaestra Goetalandsregionen, Goteborg · Region Skane Skanes Universitetssjukhus, Lund · Karolinska University Hospital, Solna
Registry updated 2026-10-20
NCT07223203
TRITON-PN: A Study to Evaluate the Efficacy and Safety of Nucresiran in Patients With Hereditary Transthyretin Amyloidosis With Polyneuropathy
Trial Treatment · Phase 3 · Alnylam Pharmaceuticals
Region Stockholm – SLSO, Stockholm · Region Vaesterbotten, Umea
Registry updated 2026-10-08
NCT07235462
A Study to Learn About the Use of Acoramidis in Patients With a Heart Condition Called Transthyretin Amyloid Cardiomyopathy (ATTR-CM) in a Real-world Setting
Research · Bayer
Many locations, Multiple Locations
Registry updated 2026-10-08
NCT06355934
OverTTuRe: Characteristics, Treatment Patterns and Outcomes of Patients With ATTR Amyloidosis
Research · AstraZeneca
Södertälje · Umeå
Registry updated 2026-09-09
NCT07116473
To Evaluate the Long-term Safety and Tolerability of Acoramidis in Participants With Newly Diagnosed ATTR-CM (ACT-EARLY OLE)
Trial Treatment · Phase 3 · Eidos Therapeutics, a BridgeBio company
Region Vaesterbotten, Umea
Registry updated 2026-08-11
NCT06563895
Acoramidis Transthyretin Amyloidosis Prevention Trial in the Young (ACT-EARLY) Study in Asymptomatic Carriers of a Pathogenic TTR Variant
Trial Treatment · Phase 3 · Eidos Therapeutics, a BridgeBio company
Region Vaesterbotten, Umea
Registry updated 2026-08-04
NCT05697861
Long-Term Follow-Up (LTFU) of Subjects Dosed With NTLA-2001
Research · Phase 2/3 · Intellia Therapeutics
Region Vaesterbotten, Umea
Registry updated 2026-08-03
NCT05667493
An Extension Study to Assess Long-Term Safety of Eplontersen in Adults With Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR-CM)
Trial Treatment · Phase 3 · Ionis Pharmaceuticals, Inc.
Sahlgrenska Universitetssjukhuset, Gothenburg · Skellefteå lasarett, Skellefteå
Registry updated 2026-04-17
NCT07413081
Increased Pacemaker Lower Rate in ATTR Cardiac Amyloidosis
Trial Treatment · Region Skane
Sahlgrenska University Hospital, Gothenburg · Linkoping University Hospital, Linköping · Skåne University Hospital, Lund · Skellefteå hospital, Skellefteå · Karolinska University Hospital, Stockholm · Norrland University Hospital, Umeå · Academic University Hospital, Uppsala
Registry updated 2026-02-17
NCT03527342
Sahlgrenska Cardiomyopathy Project
Research · Göteborg University
Göteborg University, Sahlgrenska Universitetssjukhuset, Gothenburg
Registry updated 2018-11-06

All Amyloidosis trials and the map

This page is not medical advice. Talk to your doctor before contacting a trial.

Report an error